Clonality in juvenile chronic myelogenous leukemia.
Juvenile chronic myelogenous leukemia (JCML) is a myeloproliferative disease in which morbidity and mortality are primarily caused by nonhematopoietic organ failure from myelomonocytic infiltration or by failure of the normal bone marrow. Morphologic evidence of maturation arrest, karyotypic abnormalities, and progression to blast crisis are infrequent events. Viral infections and other reactive processes can initially mimic the clinical course of JCML, creating diagnostic problems. Because of the rarity of JCML and technical limitations, formal clonality studies have not been reported previously. Nine female JCML patients were identified by clinical criteria, characteristic 'spontaneous' in vitro cell growth, and negative cultures and titers for various viral agents. Peripheral blood and bone marrow samples were obtained at the time of diagnosis for cell separation and RNA and DNA isolation. To assess clonality, X-chromosome inactivation patterns were evaluated using three different, recently developed polymerase chain reaction-based clonality assays. All nine female JCML patients showed evidence for monoclonal origin of mononuclear cells at the time of diagnosis. Cell separation studies further traced the monoclonal origin back to at least the most primitive myeloid progenitor cell. Reversion to a polyclonal state was demonstrated after bone marrow transplant and also in one patient following treatment with 13-cis retinoic acid. This demonstration of clonality in JCML delineates it from the reactive processes and provides a basis for molecular genetic strategies to identify causally associated mutations.
Busque
L
L
Division of Hematology-Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Gilliland
D G
DG
Prchal
J T
JT
Sieff
C A
CA
Weinstein
H J
HJ
Sokol
J M
JM
Belickova
M
M
Wayne
A S
AS
Zuckerman
K S
KS
Sokol
L
L
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002469:Cell Separation; D002648:Child; D002675:Child, Preschool; D002999:Clone Cells / Q000737:chemistry / Q000473:pathology*; D004247:DNA / Q000032:analysis / Q000378:metabolism; D004303:Dosage Compensation, Genetic; D005260:Female; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D010735:Phosphoglycerate Kinase / Q000235:genetics; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011944:Receptors, Androgen / Q000235:genetics; D014212:Tretinoin / Q000627:therapeutic use; D014960:X Chromosome
D011944:Receptors, Androgen; D014212:Tretinoin; D004247:DNA; D005954:Glucosephosphate Dehydrogenase; D010735:Phosphoglycerate Kinase